Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02128230 · ClinicalTrials.gov registry record · Phase 2
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
A Phase 2 study, sponsored by University of Arkansas.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02128230 is a Phase 2 study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 20 participants.
The verdict
NCT02128230, a Phase 2 study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to improve the clinical outcomes of research subjects with high-risk multiple myeloma in the context of the immediately preceding Total therapy 5 trial 2008-02 and Total therapy 3 trials 2003-33 and 2006-66.
Interventions
- DEVICE myPRS
- DRUG Induction 1 - MEL-10+CFZ-TD-PACE
- DRUG First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)
- DRUG Inter-Therapy - MEL-20+CFZ-TD-PACE (75%)
- DRUG Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-06-10 |
| Est. Completion | 2019-02-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02128230
The ClinicalTrials.gov registry entry for NCT02128230 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which myPRS is the first listed.
NCT02128230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02128230 about?
NCT02128230 is a clinical study titled "UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission". The purpose of this study is to improve the clinical outcomes of research subjects with high-risk multiple myeloma in the context of the immediately preceding Total therapy 5 trial 2008-02 and Total therapy 3 trials 2003-33 and 2006-66.
What is the current status of trial NCT02128230?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2014-06-10. Estimated completion is 2019-02-19.
What interventions are being tested in trial NCT02128230?
The interventions under investigation include: myPRS (DEVICE), Induction 1 - MEL-10+CFZ-TD-PACE (DRUG), First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic) (DRUG), Inter-Therapy - MEL-20+CFZ-TD-PACE (75%) (DRUG), Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic) (DRUG).
Who is sponsoring clinical trial NCT02128230?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.